International Headache Congress 2023

The site of action of CGRP inhibitors is likely to be in the periphery where the headache begins – in the meninges and possibly trigeminal ganglion. But, when the pain signal from the periphery has been eliminated, there is a secondary, indirect central effect on the excitability of neurones in the cortical, hypothalamic and possibly …

Using atogepant 60 mg once daily (QD) for prevention of episodic migraine and ubrogepant 100 mg as needed (PRN) for acute treatment appears safe and well tolerated over 12 weeks. In a Phase 4, multicentre, open US study, 262 participants were initially treated with atogepant 60 mg (QD) for 12 weeks. In period 2, with …

New data showing detection of fremanezumab in cerebrospinal fluid (CSF), and demonstrating target engagement, have fuelled the debate over whether CGRP mAbs are active centrally as well as peripherally. In an open label phase 1 study in healthy volunteers, a single dose of fremanezumab was infused (n=19; 900 mg; i.v.), and a single CSF sample and …

Real world registry data on nearly 5000 patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) treated with CGRP mAbs in seven European countries since January 2019 have confirmed the efficacy, tolerability and safety seen in clinical trials.1,2 At baseline, patients had 20.0 (14.0, 28.0) headache days per month (HDM), 15.0 (10.0, 20.0) migraine …

More patients with migraine have a clinically meaningful response to galcanezumab than amitriptyline and topiramate, according to results of TRIUMPH, an ongoing, international observational study in patients with migraine with ≥4 migraine headache days in the 30 days before they were initiated or switched to a preventive medication. Data on a total of 2879 patients from …